Biogen - Биоген - Photos | Facebook
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug | Fierce Biotech
Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analyst | Fierce Pharma
Biogen Foundation | Biogen
Biogen Seeks to Sublease Cambridge, Weston Properties - Banker & Tradesman
Biogen shakes up R&D role, splitting it into two
Biogen - Биоген - Photos | Facebook
Biogen's stock rises 3% after releasing new data on late-stage Alzheimer's drug
Code of Business Conduct | Biogen
Biogen - Биоген - Photos | Facebook
Biogen doubles up on deals for small molecules
Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug | Barron's
Biogen Plunges After Making Changes to Alzheimer's Drug Trial | BioSpace
Home | Biogen
Biogen (@biogen) / Twitter
Under-pressure Biogen aims to please restive investors with bigger, better board | Fierce Pharma
UPDATE: Sandrock makes a sharp exit, retiring as Biogen R&D chief amid fallout from Aduhelm approval | Fierce Biotech
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
Biogen-C | Rachael Rosewood Skin Clinic
Pipeline | Biogen
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Home | Biogen
Broad scales up as Biogen scales back in Kendall Square - The Boston Globe
